Richard Aberman’s Post

🗞 Breaking News! 🗞 We are thrilled to announce we have successfully closed our 80M Euro Series B financing round. 📣 Led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures , Inkef Capital, Vi Partners, Schroders Capital and 3B Future Health Fund I & II, this funding highlights a shared vision for the potential of our portfolio of precision oral small molecules.   This significant funding will:   🚀 Accelerate development of #roginolisib for the treatment of #uvealmelanoma through a randomized Phase II study 🚀 Broaden development of roginolisib for other cancer indications, including randomized Phase II studies in #NSCLC and primary #myelofibrosis 🚀 Progress #cambritaxestat and IOA-359 programs   Watch this space as we kick off a number of Phase II studies later in 2024.   Thank you to the team, investors and collaborators who continue to support and drive iOnctura forward. Link to press release in comments ⬇ #financing #oncology #drugdevelopment

📢 We are very pleased to announce that our portfolio company iOnctura has closed a €80M Series B round, led by new investors Syncona Limited and the European Investment Council. This funding will support the late-stage development of treatments for multiple neglected and hard-to-treat cancers. Since our initial investment in 2019, iOnctura has shown exceptional proof-of-concept data for its drug candidates, roginolisib and cambritaxestat. Roginolisib will be tested in a broader patient population for uveal melanoma, non-small cell lung cancer, and primary myelofibrosis. Cambritaxestat will be further developed for fibrotic cancers like metastatic pancreatic cancer. We're excited to welcome new investors and support iOnctura in advancing these critical treatments. #financing #oncology #drugdevelopment #cancertreatment #cancerresearch

Thanks, Illumina, for the support! We at Akrivia are committed to bringing the first-of-its-kind multi-parametric (Multi-Omics) approach-based diagnostic tests that combine genomic, transcriptomic, and immune signals to design optimal treatment plans tailored to each cancer patient based on a comprehensive understanding of their tumour biology. #PrecisionOncology #IlluminaGrant #AkriviaBiosciences #MultiOmics #BreastCancer #PrecisionMedicine

The bulk of our portfolio companies have reported their earnings for Q3 and even as most biotechs struggle to attract investor interest, the story for commercial stage biotech is completely different. Still showing strong growth in both cancer and rare disease. The Rare disease space continues to be our favorite play. Of the +35 companies in the fund over 80% is commercial which explains our performance this year. #biotech #assetmanagement

We are excited to announce our largest investment round ever, through investments from existing owners Chalmers Ventures, Marinvest Holding AB, Vätterleden Holding Ventures and Erik Stromqvist, as well as new investors such as Triathlon Group Ventures, Life Science Invest (LSI Epsilon), and Ekeblad Bostad AB. - Our technology allows our customers to develop and manufacture astatine-based radiopharmaceuticals that act like microscopic guided missiles, says Milton Lönnroth, co-founder and CEO of Atley Solutions. Inside the patient's body, the pharmaceuticals can seek out and kill cancer cells without significantly affecting healthy cells and tissues. No one wants to destroy what is healthy, and an important feature of these drugs, besides their great potential for greater clinical efficacy, is that they contribute to a less toxic treatment with fewer side effects compared to current treatment methods. - We are pleased to make a follow-up investment in Atley while also bringing in new investors in this round, says Jonas Bergman, Investment Director at Chalmers Ventures. Atley have sold several products to renowned pharma companies. This is a strong testament to Atley's potential. We are now entering the next phase and aims for scaling up a technology that creates both positive impact and good business. More info (scroll down for English version): https://lnkd.in/ghwbPh5T #deeptech #radiopharmaceuticals #astatine211 #targetedradionuclidetherapy #cancertreatment

Read more about our latest investment below 🙌!!

#fundingalert 💼Company: Matter Bio 💰Funding: $7Million ⚡Round: Seed 👥Investors: quadraScope Ventures and other investors, Lifespan Vision Ventures led the round. NIH, NCI, and NIEHS provided grants for the project. Maintaining genetic integrity is the primary goal of Matter Bio, a lifespan holding business. Both endogenous and external factors continuously harm their genome as they become older. The company plans to file an IND, begin a Phase 1/2a clinical trial in solid cancer, and carry out additional research into the information theory of ageing at a genetic level with the money. George Church, Sam Sharifi, PhD, Harry Robb, Christopher Bradley Read more - https://lnkd.in/gjzaaVdE To share your startup story write us on - [email protected] #MatterBio #endogenous #geneticlevel #funding #fundingnews #news #startup #startupnews #startuprise

#fundingalert 💼Company: Vandria SA 💰Funding: $30.7Million ⚡Round: Series A 👥Investors: Hevolution Foundation, Dolby Family Ventures, ND Capital Vandria is at the vanguard of #mitochondrial therapeutics. It is developing first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318 is a brain-penetrant, patent-protected, mitophagy inducer which has been shown to acutely improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s disease. Klaus Dugi, Sourav Kole, Jens Eckstein, Pénélope Andreux   Read more - https://lnkd.in/g4stGm89 To share your startup story write us on - [email protected] #Vandria #NDCapital #Medtech #neurodegenerative #News #Fundraising #Funding #startup #Europeanstartup

Mark McKenna and several former Prometheus executives just unveiled their next venture: Mirador Therapeutics, a new biotech developing treatments for immune-driven conditions affecting the gastrointestinal tract, lung, and skin. Investment in immunology and inflammatory conditions have quickly risen to the top of venture capitalists’ wish lists. There has been innovation in this space, but there’s plenty of room for improvement in unraveling the workings of the immune system, ARCH Venture Partners managing directors Kristina Burow and Paul Berns said. And McKenna’s success with Prometheus was still fresh in people’s minds — early investors in his last biotech earned a 30x return on their investments. Read on to hear how the Mirador team doubled their fundraising goal. #biotech #biopharma #startups #immunology #immunesystem #inflammation #venturecapital #VC #startupstrategies STAT

Cure51, the TechBio startup that reverse engineering exceptional Cancer Survivors biology, raises €15M from world class life science and healthcare VCs. Cure51 was co-founded by Nicolas Wolikow and Simon Istolainen with unconditional support and inputs from Thomas Clozel, Owkin Co-founder and CEO. #oncology #drugdiscovery #biotechnology #cancersurvivor #outliers #healthtech #biotech #fundingnews  #techpr #venturecapital  #seedfunding  #seedinvestment #techstartup #startupnews